This database contains 24 studies, archived under the term: "Biological Testing"
Click here to filter this large number of results.
Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer’s disease
Portelius, Erik,
Zetterberg, Henrik,
Dean, Robert A.,
Marcil, Alexandre,
Bourgeois, Philippe,
Nutu, Magdalena,
Andreasson, Ulf,
Siemers, Eric,
Mawuenyega, Kwasi G.,
Sigurdson, Wendy C.,
May, Patrick C.,
Paul, Steven M.,
Holtzman, David M.,
Blennow, Kaj,
Bateman, Randall J.
Amyloid-β (Aβ) producing enzymes are key targets for disease-modifying Alzheimer’s disease (AD) therapies since Aβ trafficking is at the core of AD pathogenesis. Development of such drugs might benefit from the identification of markers indicating in vivo drug effects in the central nervous system. We have previously shown that Aβ(1-15) is produced by concerted β-and […]
Diagnostic and economic evaluation of new biomarkers for Alzheimer’s disease: the research protocol of a prospective cohort study
Handels, Ron L.H.,
Aalten, Pauline,
Wolfs, Claire A.G.,
OldeRikkert, Marcel,
Scheltens, Philip,
Visser, Pieter Jelle,
Joore, Manuela A.,
Severens, Johan L.,
Verhey, Frans R.J.
Background: New research criteria for the diagnosis of Alzheimer’s disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers. To enable efficient allocation of health care resources, evidence is needed to support decision makers on the adoption of emerging biomarkers in clinical practice. The research goals […]
Safety of lumbar puncture procedures in patients with Alzheimer’s disease
Changes in cerebrospinal fluid (CSF) biomarkers are representative of biochemical changes in the brain. Collection of CSF by lumbar puncture (LP) is essential for biomarker analysis, which is important for research in neurodegenerative disorders. However, LP for research purposes has been controversial due to a reported high incidence of severe LP headache when using standard […]
CSF biomarker profile and diagnostic value in vascular dementia
Paraskevas, G. P.,
Kapaki, E.,
Papageorgiou, S. G.,
Kalfakis, N.,
Andreadou, E.,
Zalonis, I.,
Vassilopoulos, D.
Background and Purpose: The differential diagnosis between vascular dementia (VD) and Alzheimer’s disease (AD) or mixed dementia (MD) is not always easy in clinical practice. The purpose of the present study was to evaluate the cerebrospinal fluid (CSF) biomarkers tau protein in its total (tau(T)) or hyperphosphorylated at threonin-181(tau(P-181)) form and beta amyloid peptide 1-42 […]
Urine neural thread protein measurements in Alzheimer disease
Objectives: Neural thread protein (NTP), a membrane-associated phosphoprotein, was selectively elevated in the urine of patients with Alzheimer disease (AD). To demonstrate the potential utility of urine NTP assays for the diagnosis of AD, we performed this study.; Design: A prospective blinded multicentered study.; Participants: Individuals diagnosed as having probable AD (n = 49), Parkinson’s […]
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
Unterberger, Ursula,
Lachmann, Ingolf,
Voigtländer, Till,
Pirker, Walter,
Berghoff, Anna S.,
Flach, Katharina,
Wagner, Uta,
Geneste, Aline,
Perret-Liaudet, Armand,
Kovacs, Gabor G.
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of […]
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years
Stoeck, K.,
Sanchez-Juan, P.,
Gawinecka, J.,
Green, A.,
Ladogana, A.,
Pocchiari, M.,
Sanchez-Valle, R.,
Mitrova, E.,
Sklaviadis, T.,
Kulczycki, J.,
Slivarichova, D.,
Saiz, A.,
Calero, M.,
Knight, R.,
Aguzzi, A.,
Laplanche, J.-L.,
Peoc'h, K.,
Schelzke, G.,
Karch, A.,
van Duijn, C. M.,
Zerr, I.
To date, cerebrospinal fluid analysis, particularly protein 14-3-3 testing, presents an important approach in the identification of Creutzfeldt-Jakob disease cases. However, one special point of criticism of 14-3-3 testing is the specificity in the differential diagnosis of rapid dementia. The constant observation of increased cerebrospinal fluid referrals in the national surveillance centres over the last […]
ERK2 is increased in cerebrospinal fluid of Creutzfeldt-Jakob disease patients
Steinacker, Petra,
Klafki, Hans,
Lehnert, Stefan,
Jesse, Sarah,
Arnim, Christine A. F. V.,
Tumani, Hayrettin,
Pabst, Alice,
Kretzschmar, Hans A.,
Wiltfang, Jens,
Otto, Markus
The clinical diagnosis of Creutzfeldt-Jakob disease (CJD) can be supported by several biochemical markers in cerebrospinal fluid (CSF) such as 14-3-3 proteins and tau protein. Unfortunately, none of the currently known markers are suited for screening or seems to be directly related to the pathophysiological process. A marker fulfilling these criteria might facilitate the early […]
CSF α-synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans
Spies, Petra E.,
Slats, Diane,
Olde Rikkert, Marcel G. M.,
Tseng, Jack,
Claassen, Jurgen A. H. R.,
Verbeek, Marcel M.
Reports on the value of cerebrospinal fluid (CSF) α-synuclein as a biomarker for dementia with Lewy bodies and Parkinson disease are contradicting. This may be explained by fluctuating CSF α-synuclein concentrations over time. Such fluctuations have been suggested for CSF amyloid β concentrations. Furthermore, a physiological relationship between α-synuclein and amyloid β has been suggested […]